 |
|
|
| |
Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 2 mg Once Daily for 6 Days in Participants With Moderate and Severe Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function
|
| |
| |
AASLD Nov 15-19, 2024 San Diego, CA
Parag Kumar, Renee-Claude Mercier, Wildaliz Nieves, David Pan, Steve Tseng, Grace M Chee, Xu Zhang, Yehong Wang, Ann Qin, Carrie Nielson, Teckla Akinyi, Helen Winter
Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
